Literature DB >> 11859969

Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression.

M Simon1, T W Park, G Köster, R Mahlberg, M Hackenbroch, J Boström, T Löning, J Schramm.   

Abstract

Dysregulation of cell cycle progression and telomerase activation have been implicated in malignant tumor progression as well as in the evasion of senescence and immortalization. We have investigated expression of the cell cycle control and tumor suppressor genes INK4a(p16-p14ARF), INK4b(p15-p10) and RB, and their relation to telomerase activation during malignant meningioma progression. 7/26 (27%) benign, 3/12 (25%) atypical but 4/7 (57%) anaplastic tumors lacked both, p16 and p15 protein expression. 14/39 (36%) benign and atypical but 5/7 (71%) anaplastic meningiomas contained no p14ARF mRNA. 2/46 (4%) tumors failed to express pRB. We observed frequent differential loss of expression of the alternatively spliced INK4a tumor suppressors p16 and p14ARF. Exclusive expression of the alternative INK4b transcript p10 possibly at the expense of p15 and therefore resulting in loss of p15 tumor suppressor activity was noted in two meningiomas. We have previously described telomerase activity or expression of the telomerase catalytic subunit hTERT in this meningioma series. Telomerase activation was detected in 10/27 (37%) benign, but 18/19 (95%) non-benign meningiomas. We observed no significant overall correlation between loss of INK4a/INK4b expression and telomerase activation. In conclusion, our results suggest a greater role for losses of INK4a/INK4b gene products in meningioma formation and malignant progression than previously thought. Inactivation of p16/p15- and pl4ARF-dependent pathways possibly in conjunction with telomerase activation might be critical steps for a meningioma cell towards escape from senescence, that is, immortalization.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11859969     DOI: 10.1023/a:1013863630293

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  41 in total

Review 1.  Telomerase activation. One step on the road to cancer?

Authors:  C W Greider
Journal:  Trends Genet       Date:  1999-03       Impact factor: 11.639

2.  Analysis of cell cycle regulators: p16INK4A, pRb, and CDK4 in low- and high-grade meningiomas.

Authors:  J Y Tse; H K Ng; K W Lo; E Y Chong; P Y Lam; E K Ng; W S Poon; D P Huang
Journal:  Hum Pathol       Date:  1998-11       Impact factor: 3.466

3.  Exogenous expression of p16INK4a is associated with decrease in telomerase activity.

Authors:  H Sawa; H Kamada; T A Ohshima; A Noguchi; N Itoh; K Saruta; M Hara; I Saito
Journal:  J Neurooncol       Date:  1999-03       Impact factor: 4.130

4.  Cloning and characterization of p10, an alternatively spliced form of p15 cyclin-dependent kinase inhibitor.

Authors:  M Tsubari; E Tiihonen; M Laiho
Journal:  Cancer Res       Date:  1997-07-15       Impact factor: 12.701

5.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

6.  Expression of p53, MDM2 protein and Ki-67 antigen in recurrent meningiomas.

Authors:  M Ohkoudo; H Sawa; M Hara; K Saruta; T Aiso; R Ohki; H Yamamoto; E Maemura; Y Shiina; M Fujii; I Saito
Journal:  J Neurooncol       Date:  1998-05       Impact factor: 4.130

7.  Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases.

Authors:  L Palma; P Celli; C Franco; L Cervoni; G Cantore
Journal:  J Neurosurg       Date:  1997-05       Impact factor: 5.115

8.  Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest.

Authors:  D E Quelle; F Zindy; R A Ashmun; C J Sherr
Journal:  Cell       Date:  1995-12-15       Impact factor: 41.582

9.  Detection of TP53 gene mutation in human meningiomas: a study using immunohistochemistry, polymerase chain reaction/single-strand conformation polymorphism and DNA sequencing techniques on paraffin-embedded samples.

Authors:  J L Wang; Z J Zhang; M Hartman; A Smits; B Westermark; C Muhr; M Nistér
Journal:  Int J Cancer       Date:  1995-08-22       Impact factor: 7.396

10.  Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells.

Authors:  T Kiyono; S A Foster; J I Koop; J K McDougall; D A Galloway; A J Klingelhutz
Journal:  Nature       Date:  1998-11-05       Impact factor: 49.962

View more
  16 in total

1.  Fatty acid synthase is a predictive marker for aggressiveness in meningiomas.

Authors:  Keishi Makino; Hideo Nakamura; Taku-ichiro Hide; Shigetoshi Yano; Jun-Ichiro Kuroda; Ken-Ichi Iyama; Jun-Ichi Kuratsu
Journal:  J Neurooncol       Date:  2012-06-29       Impact factor: 4.130

2.  Oncogenic role of p53 is suppressed by si-RNA bicistronic construct of uPA, uPAR and cathepsin-B in meningiomas both in vitro and in vivo.

Authors:  Reshu Gupta; Venkateswara Rao Gogineni; Arun Kumar Nalla; Chandramu Chetty; Jeffrey D Klopfenstein; Andrew J Tsung; Sanjeeva Mohanam; Jasti S Rao
Journal:  Int J Oncol       Date:  2011-02-02       Impact factor: 5.650

3.  Diagnostic and prognostic significance of genetic regional heterogeneity in meningiomas.

Authors:  Wolfgang K Pfisterer; Nicole C Hank; Mark C Preul; William P Hendricks; Jeanette Pueschel; Stephen W Coons; Adrienne C Scheck
Journal:  Neuro Oncol       Date:  2004-10       Impact factor: 12.300

4.  hTERT promoter methylation in meningiomas and central nervous hemangiopericytomas.

Authors:  Gina Fürtjes; Michaela Köchling; Susanne Peetz-Dienhart; Andrea Wagner; Katharina Heß; Martin Hasselblatt; Volker Senner; Walter Stummer; Werner Paulus; Benjamin Brokinkel
Journal:  J Neurooncol       Date:  2016-07-27       Impact factor: 4.130

5.  N-ethyl-N-nitrosourea (ENU)-induced meningiomatosis and meningioma in p16(INK4a)/p19(ARF) tumor suppressor gene-deficient mice.

Authors:  James P Morrison; Hiroshi Satoh; Julie Foley; John L Horton; June K Dunnick; Grace E Kissling; David E Malarkey
Journal:  Toxicol Pathol       Date:  2007-10       Impact factor: 1.902

6.  A genetic strategy to overcome the senescence of primary meningioma cell cultures.

Authors:  Gilson S Baia; Alison L Slocum; Jeanette D Hyer; Anjan Misra; Nouzhan Sehati; Scott R VandenBerg; Burt G Feuerstein; Dennis F Deen; Michael W McDermott; Anita Lal
Journal:  J Neurooncol       Date:  2006-03-23       Impact factor: 4.130

7.  Molecular biology of unreresectable meningiomas: implications for new treatments and review of the literature.

Authors:  Jay Jagannathan; Rod J Oskouian; Hian Kwang Yeoh; Dwight Saulle; Aaron S Dumont
Journal:  Skull Base       Date:  2008-05

Review 8.  Therapeutic targets in the ARF tumor suppressor pathway.

Authors:  Anthony J Saporita; Leonard B Maggi; Anthony J Apicelli; Jason D Weber
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

Review 9.  MEG3: a novel long noncoding potentially tumour-suppressing RNA in meningiomas.

Authors:  Vladimir Balik; Josef Srovnal; Igor Sulla; Ondrej Kalita; Tatiana Foltanova; Miroslav Vaverka; Lumir Hrabalek; Marian Hajduch
Journal:  J Neurooncol       Date:  2013-01-11       Impact factor: 4.130

10.  Effects of p16 gene on biological behaviours in hepatocellular carcinoma cells.

Authors:  Jian-Zhao Huang; Sui-Sheng Xia; Qi-Fa Ye; Han-Ying Jiang; Zhong-Hua Chen
Journal:  World J Gastroenterol       Date:  2003-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.